Marco Amedeo Cimmino

Marco Amedeo Cimmino

Auto-generated profile, based on publicly available information

Marco Amedeo Cimmino

Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Italy

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LCLorenzo Cavagna
Lorenzo Cavagna
ETErnesto Trallero-Araguás
Ernesto Trallero-Araguás
FMFederica Meloni
Federica Meloni
Ilaria CavazzanaIlaria Cavazzana
Ilaria Cavazzana
JRJorge Rojas-Serrano
Jorge Rojas-Serrano
Miguel Angel Gonzalez-GayMiguel Angel Gonzalez-Gay
Miguel Angel Gonzalez-Gay
Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung disease (ILD), along with specific autoantibodies that are addressed to different aminoacyl tRNA synthetases (ARS). Until now, it has been unknown whether the presence of a different ARS might affect the clinical presentation, evolution, and outcome of ASSD. In this study, we retrospectively recorded the time of onset, characteristics, clustering of triad findings, and survival of 828 ASSD patients (593 anti-Jo1, 95 anti-PL7, 84 anti-PL12, 38 anti-EJ, and 18 anti-OJ), referring to AENEAS (American and European NEtwork of Antisynthetase Syndrome) collaborative group’s cohort. Comparisons were performed first between all ARS cases and then, in the case of significance, while using anti-Jo1 positive patients as the reference group. The characteristics of triad findings were similar and the onset mainly began with a single triad finding in all groups despite some differences in overall prevalence. The “ex-novo” occurrence of triad findings was only reduced in the anti-PL12-positive cohort, however, it occurred in a clinically relevant percentage of patients (30%). Moreover, survival was not influenced by the underlying anti-aminoacyl tRNA synthetase antibodies’ positivity, which confirmed that antisynthetase syndrome is a heterogeneous condition and that antibody specificity only partially influences the clinical presentation and evolution of this condition.

6 May 2003 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
MCMarco A. Cimmino
Marco A. Cimmino
SIStefania Innocenti
Stefania Innocenti
FLFabrizio Livrone
Fabrizio Livrone
FMFrancesca Magnaguagno
Francesca Magnaguagno
ESEnzo Silvestri
Enzo Silvestri
GGGiacomo Garlaschi
Giacomo Garlaschi
Objective: To determine the efficacy of dynamic gadolinium‐enhanced magnetic resonance imaging (MRI) of the wrist in the evaluation of disease activity in patients with rheumatoid arthritis (RA).Methods: Thirty‐six patients with RA (with different degrees of disease activity) and 5 healthy controls were studied. MRI was performed with a low‐field (0.2T), extremity‐dedicated machine. After an intravenous bolus injection of gadolinium–diethylenetriamine pentaacetic acid, 20 consecutive fast spin‐echo images of 3 slices of the wrist were obtained every 18 seconds.Results: The curves of synovial membrane enhancement identified the following 2 groups: controls and RA patients in remission, and RA patients with active or intermediately active disease. Both the rate of early enhancement (REE) and relative enhancement (RE) were significantly higher in patients with active RA than in those with inactive RA and controls. The REE and RE were significantly correlated with the number of swollen joints (P < 0.00001 and P = 0.003, respectively), the number of tender joints (P < 0.00001 and P = 0.004, respectively), the Ritchie index (P = 0.0002 for both REE and RE), the Disease Activity Score (P = 0.0004 and P = 0.0008, respectively), the Health Assessment Questionnaire (HAQ) (P = 0.0002 and P = 0.0007, respectively), early morning stiffness (P = 0.001 and P = 0.009, respectively), the C‐reactive protein level (P = 0.015 and P = 0.03, respectively), the erythrocyte sedimentation rate (P = 0.03, RE only), and α2 globulins (P = 0.036 and P = 0.028, respectively).Conclusion: Our data support use of dynamic MRI for discriminating active from inactive RA. Enhancement curves are associated not only with laboratory and clinical indicators of inflammation, but also with the HAQ, a relevant predictor of RA functional outcome. This technique can be repeated frequently and is an excellent candidate for the ideal method for the followup of patients with RA.

27 September 2000 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
MCM. A. Cimmino
M. A. Cimmino
SCSalvarani Carlo
Salvarani Carlo
PMP. Macchioni
P. Macchioni
CMCarlomaurizio Montecucco
Carlomaurizio Montecucco
VFV. Fossaluzza
V. Fossaluzza
RNR. Numo
R. Numo

3 September 2013 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
CSCarlo Alberto Scirè
Carlo Alberto Scirè
MMMaria Manara
Maria Manara
MCMarco Amedeo Cimmino
Marco Amedeo Cimmino
MGMarcello Govoni
Marcello Govoni
FSFausto Salaffi
Fausto Salaffi
KCKING Study Collaborators
KING Study Collaborators
Introduction: Gout is the most prevalent arthritis and significantly impacts on function and quality of life. Given that gout associates with disabling comorbid conditions, it is not clear whether such a complex of diseases accounts for the increased disability or if gout may play a role by itself. This study aims to evaluate the specific influence of gout and disease-related features on functional disability and health-related quality of life (HRQoL) in patients with gout followed in rheumatology clinics. Methods: A random sample of patients was drawn from clinical registries of 30 rheumatology clinics across Italy. Sociodemographic, general health and gout-specific variables were collected. Functional disability and HRQoL were assessed by the health assessment questionnaire (HAQ) and the Physical and Mental Component Summary scores (PCS and MCS) of the Short Form-36 (SF-36). Crude and adjusted ordinal logistic and linear regression models were applied to investigate the specific contribution of different variables on HAQ and SF-36 scores. Results are presented as odds ratio (OR) or mean difference (MD) and 95% confidence intervals. Results: Out of 446 patients with gout, 90% were males with a mean age of 63.9 years and median disease duration of 3.8 years; the majority of patients were overweight or obese, and with several comorbidities; 21.1% showed at least moderate disability; the PCS score was significantly lower than expected age- and gender-matched samples in the general population, while MCS score was not. After adjusting for potential sociodemographic and general-health confounders, gout-specific variables significantly impacted on HAQ, including polyarticular involvement OR 3.82 (1.63, 8.95), presence of tophi OR 1.92 (1.07, 3.43) and recent attacks OR 2.20 (1.27, 3.81). Consistent results were found for PCS. The impairment of PCS compared to the general population was limited to patients with features of chronic gout. MCS was only affected by recent attacks (MD -2.72 [-4.58, -0.86]) and corticosteroid treatment (-3.39 [-5.30,-1.48]). Conclusions: The data from the KING study confirm that gout impacts on disability and provide evidence for an independent association of gout and gout-related features with functional outcome and HRQoL. This result supports the need to improve specific treatment in gout.

1 April 2005 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
MCMarco A Cimmino
Marco A Cimmino
MPMassimiliano Parodi
Massimiliano Parodi
SIStefania Innocenti
Stefania Innocenti
GSGiulia Succio
Giulia Succio
SBSimone Banderali
Simone Banderali
GGGiacomo Garlaschi
Giacomo Garlaschi
This dynamic magnetic resonance imaging (MRI) study is concerned with a prospective evaluation of wrist synovitis in patients with psoriatic arthritis (PsA) in comparison with patients with rheumatoid arthritis (RA) and healthy controls. Fifteen consecutive patients with PsA, 49 consecutive patients with RA, 30 RA patients matched for disease severity with those with PsA, and 8 healthy controls were studied. MRI was performed with a low-field (0.2T), extremity-dedicated machine. After an intravenous bolus injection of gadolinium-diethylenetriaminepentaacetic acid, 20 consecutive fast spin-echo axial images of the wrist were obtained every 18 s. The enhancement ratio was calculated both as rate of early enhancement (REE), which shows the slope of the curve of contrast uptake per second during the first 55 s, and as relative enhancement (RE), which indicates the steady state of enhancement. The REE was 1.0 ± 0.6 in patients with PsA, 1.6 ± 0.7 in consecutive patients with RA, and 0.1 ± 0.1 in controls (p <0.001). The RE was 87.1 ± 39.2 in patients with PsA, 125.8 ± 48.0 in consecutive RA patients, and 15.5 ± 19.2 in controls (p <0.001). However, the same figures in matched RA patients were 1.3 ± 0.7 and 107.3 ± 48.2, respectively (not significant in comparison with PsA). Rheumatoid-like PsA and oligoarticular PsA did not differ from each other in terms of synovial enhancement. Dynamic MRI shows the same pattern of synovitis in patients with PsA and RA when the two groups are matched for disease severity. This technique cannot be used to differentiate PsA from RA. However, REE and RE were significantly higher in PsA than in normal controls, with only one instance of overlap between values found for the two groups.

1 August 2005 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
PDF file
MCMarco A. Cimmino
Marco A. Cimmino
Piercarlo Sarzi-PuttiniPiercarlo Sarzi-Puttini
Piercarlo Sarzi-Puttini
RSRaffaele Scarpa
Raffaele Scarpa
RCRoberto Caporali
Roberto Caporali
Fabio ParazziniFabio Parazzini
Fabio Parazzini
RMRoberto Marcolongo
Roberto Marcolongo